Rhumbline Advisers Gilead Sciences, Inc. Transaction History

Rhumbline Advisers

  • $103 Billion
  • Q1 2024

A detailed history of Rhumbline Advisers transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 2,460,538 shares of GILD stock, worth $169 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
2,460,538
Previous 2,822,190 12.81%
Holding current value
$169 Million
Previous $229 Million 21.17%
% of portfolio
0.18%
Previous 0.24%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024
SELL
$71.58 - $87.29 $25.9 Million - $31.6 Million
-361,652 Reduced 12.81%
2,460,538 $180 Million
Q4 2023

Feb 08, 2024
SELL
$73.27 - $83.09 $2.92 Million - $3.32 Million
-39,919 Reduced 1.39%
2,822,190 $229 Million
Q3 2023

Nov 09, 2023
BUY
$73.94 - $80.67 $5.36 Million - $5.85 Million
72,535 Added 2.6%
2,862,109 $214 Million
Q2 2023

Aug 08, 2023
SELL
$76.01 - $86.7 $241,407 - $275,359
-3,176 Reduced 0.11%
2,789,574 $215 Million
Q1 2023

May 11, 2023
BUY
$77.31 - $88.08 $4.33 Million - $4.93 Million
55,961 Added 2.04%
2,792,750 $232 Million
Q4 2022

Feb 14, 2023
BUY
$62.32 - $89.47 $2.67 Million - $3.83 Million
42,809 Added 1.59%
2,736,789 $235 Million
Q3 2022

Nov 10, 2022
BUY
$59.54 - $68.01 $26.7 Million - $30.5 Million
447,874 Added 19.94%
2,693,980 $166 Million
Q2 2022

Aug 11, 2022
BUY
$57.72 - $65.01 $6.18 Million - $6.96 Million
107,019 Added 5.0%
2,246,106 $139 Million
Q1 2022

May 12, 2022
BUY
$57.92 - $72.58 $1.98 Million - $2.48 Million
34,162 Added 1.62%
2,139,087 $127 Million
Q4 2021

Feb 10, 2022
BUY
$64.88 - $73.64 $2.46 Million - $2.79 Million
37,900 Added 1.83%
2,104,925 $153 Million
Q3 2021

Nov 12, 2021
SELL
$67.69 - $73.03 $4.53 Million - $4.89 Million
-66,949 Reduced 3.14%
2,067,025 $144 Million
Q2 2021

Aug 05, 2021
SELL
$63.47 - $69.35 $7.87 Million - $8.6 Million
-123,970 Reduced 5.49%
2,133,974 $147 Million
Q1 2021

May 06, 2021
SELL
$60.0 - $68.46 $7.28 Million - $8.31 Million
-121,318 Reduced 5.1%
2,257,944 $146 Million
Q4 2020

Feb 10, 2021
SELL
$56.65 - $64.55 $7.47 Million - $8.52 Million
-131,937 Reduced 5.25%
2,379,262 $139 Million
Q3 2020

Nov 12, 2020
SELL
$62.1 - $78.08 $459,788 - $578,104
-7,404 Reduced 0.29%
2,511,199 $159 Million
Q2 2020

Aug 13, 2020
BUY
$72.34 - $84.0 $19.6 Million - $22.8 Million
271,391 Added 12.08%
2,518,603 $194 Million
Q1 2020

May 06, 2020
BUY
$62.63 - $80.22 $2.81 Million - $3.6 Million
44,892 Added 2.04%
2,247,212 $168 Million
Q4 2019

Feb 05, 2020
BUY
$61.62 - $67.78 $1.78 Million - $1.96 Million
28,860 Added 1.33%
2,202,320 $143 Million
Q3 2019

Oct 23, 2019
BUY
$62.51 - $69.0 $2.68 Million - $2.96 Million
42,854 Added 2.01%
2,173,460 $138 Million
Q2 2019

Aug 14, 2019
SELL
$61.87 - $69.38 $789,399 - $885,219
-12,759 Reduced 0.6%
2,130,606 $144 Million
Q1 2019

May 01, 2019
BUY
$62.53 - $70.05 $3.55 Million - $3.97 Million
56,702 Added 2.72%
2,143,365 $139 Million
Q4 2018

Jan 31, 2019
BUY
$60.54 - $79.0 $116,176 - $151,601
1,919 Added 0.09%
2,086,663 $131 Million
Q3 2018

Nov 07, 2018
SELL
$71.28 - $78.92 $2.22 Million - $2.46 Million
-31,147 Reduced 1.47%
2,084,744 $161 Million
Q2 2018

Aug 06, 2018
SELL
$64.88 - $75.68 $15 Million - $17.4 Million
-230,447 Reduced 9.82%
2,115,891 $150 Million
Q1 2018

May 02, 2018
SELL
$72.84 - $88.8 $5.43 Million - $6.61 Million
-74,481 Reduced 3.08%
2,346,338 $177 Million
Q4 2017

Feb 09, 2018
BUY
$71.15 - $83.52 $7.18 Million - $8.43 Million
100,935 Added 4.35%
2,420,819 $173 Million
Q3 2017

Nov 06, 2017
BUY
$72.11 - $85.47 $167 Million - $198 Million
2,319,884
2,319,884 $188 Million

Others Institutions Holding GILD

# of Institutions
1,884
Shares Held
1B
Call Options Held
8.71M
Put Options Held
8.02M
View Full List

About GILEAD SCIENCES, INC.

GILD Quotes by TradingView
  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $86B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email